Lantern reports complete response in pretreated Lymphoma patient with LP-284

Lantern Pharma (LTRN) announced that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma achieved a complete metabolic response in the ongoing Phase 1 clinical trial of LP-284. This represents the first complete response observed with LP-284 and displays profound clinical activity in one of the most therapeutically challenging hematologic cancers. The RADR-driven, AI approach enables Lantern to rapidly determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimize combination strategies for the clinical setting. The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months over the last 15 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy, and CD3xCD20 bispecific antibody therapy. Following enrollment in April, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. This clinical outcome supports LP-284’s synthetic lethal mechanism. Despite achieving an initial complete metabolic response with CAR-T therapy at day 30, the patient experienced disease progression by day 90. Subsequent treatment with the CD3xCD20 bispecific antibody glofitamab resulted in progressive disease with multifocal new lesions. At study entry on the LP-284-Phase 1 trial in April 2025, the patient presented with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips – representing an extremely challenging clinical scenario. The achievement of complete metabolic response with non-avid lesions following just two cycles of LP-284 therapy represents a potential future alternative for treating therapeutically exhausted DLBCL patients. Lantern plans to continue enrollment in the Phase 1 trial while closely monitoring the responding patient and other potential future patients for durability of response and efficacy signals. The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints. The complete response achievement positions LP-284 for potential accelerated development pathways and creates opportunities for strategic partnerships as Lantern advances its synthetic lethal portfolio toward later-stage clinical trials.